Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Epitope

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    41 result(s) found for: Epitope. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2018-003323-10 Sponsor Protocol Number: V712-305(EPOPEX) Start Date*: Information not available in EudraCT
    Sponsor Name:DBV TECHNOLOGIES S.A.
    Full Title: EPITOPE OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM CLINICAL BENEFIT AND SAFETY OF DBV712 IN PEANUT-ALLERGIC CHILDREN (EPOPEX)
    Medical condition: Peanut allergy
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004870 10034202 Peanut allergy LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: IE (Completed) GB (GB - no longer in EU/EEA) NL (Trial now transitioned) DE (Trial now transitioned) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-001304-15 Sponsor Protocol Number: AZGS2021005 Start Date*: 2021-05-06
    Sponsor Name:vzw az groeninge
    Full Title: COVID-19: Study of the immune response in healthy volunteers after vaccination against SARS-CoV-2 (COVID19-VAX-AZG) and monitoring of breakthrough infections after booster vaccination (COVID19-VAX-...
    Medical condition: immuneresponse after vaccination
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-000219-24 Sponsor Protocol Number: 3082A-101342 Start Date*: 2005-04-28
    Sponsor Name:Wyeth Pharmaceuticals
    Full Title: A multicentre study to describe the immunogenic epitope(s) of factor VIII in previously treated patients with congenital haemophilia A who develop de novo factor VIII inhibitors while receiving fac...
    Medical condition: Haemophilia A is an X-linked recessive clotting disorder in which the clotting factor, factor VIII (FVIII), is deficient or inactive. Patients with low levels of FVIII have an increased tendency t...
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) ES (Completed) DE (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-018279-99 Sponsor Protocol Number: HUM07-066 Start Date*: 2010-05-05
    Sponsor Name:Faculty of Medicine, Otto-von-Guericke-University Magdeburg
    Full Title: Skin Topoproteome under Adalimumab (Humira®) Treatment in Patients with Moderate to Severe Psoriasis
    Medical condition: Disease under investigation: Adult patients of both genders with moderate to severe chronic plaque psoriasis who failed to respond to or who have a contraindication to, or are intolerant to other s...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-004752-34 Sponsor Protocol Number: 53998 Start Date*: 2019-02-20
    Sponsor Name:Amsterdam University Medical Centers location AMC
    Full Title: Study of pembrolizumab combined with ataluren in Patients with metastatic pMMR and dMMR colorectal cancer adenocarcinomas or metastatic dMMR endometrial carcinoma: the ATAPEMBRO study.
    Medical condition: Mismatch repair deficient and proficient metestatic colorectal carcinoma and mismatch repair deficient metastatic endometrial carcinoma, stomach carcinoma and small bowel carcinoma.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-005450-30 Sponsor Protocol Number: ABI-MS-P01 Start Date*: 2014-01-08
    Sponsor Name:Medizinische Universität Innsbruck
    Full Title: Anti-Biopharmaceutical Immunization: Prediction and analysis of clinical relevance to minimize the risk of immunization in multiple sclerosis patients on interferon-beta treatment
    Medical condition: Development of neutralising antibodies against Interferon-beta in the treatment of multiple sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed) SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-003679-23 Sponsor Protocol Number: EPITOPE-V712-304 Start Date*: Information not available in EudraCT
    Sponsor Name:DBV TECHNOLOGIES S.A.
    Full Title: A double-blind, placebo-controlled, randomized phase III trial to assess the safety and efficacy of Viaskin® Peanut in peanut-allergic young children 1-3 years of age (EPITOPE study)
    Medical condition: Peanut allergy
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004870 10034202 Peanut allergy LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: IE (Completed) FR (Ongoing) DE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2021-004889-35 Sponsor Protocol Number: UCDCRC/21/10 Start Date*: 2021-12-08
    Sponsor Name:University College Dublin
    Full Title: An International Multicentre, Phase 2, Randomised, Adaptive Protocol to determine the need for, optimal timing of and immunogenicity of administering a booster mRNA vaccination dose against SARS-Co...
    Medical condition: Severe Acute Respiratory Syndrome Coronavirus 19 (COVID-19/SARS-CoV-2)
    Disease: Version SOC Term Classification Code Term Level
    23.1 10042613 - Surgical and medical procedures 10084457 COVID-19 immunisation PT
    23.0 10042613 - Surgical and medical procedures 10084462 SARS-CoV-2 vaccination LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) NO (Completed) DE (Completed) ES (Ongoing) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-018517-29 Sponsor Protocol Number: DMD-UHK-B1 Start Date*: 2010-02-22
    Sponsor Name:Medical Faculty, Otto-von-Guericke-University Magdeburg
    Full Title: Topoproteome-Analysis of Psoriasis under Fumarate-Treatment.
    Medical condition: Fumaderm initial / Fumaderm will be used in this CT completely "in-label", i.e. for the treatment of adult patients of both genders with moderate to severe plaque psoriasis in so far as a solely to...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-001081-99 Sponsor Protocol Number: MS/MOGMOD/CT/FIH/01 Start Date*: 2014-12-16
    Sponsor Name:ImCyse S.A
    Full Title: A clinical trial to document safety and radiological disease activity in patients with relapsing-remitting multiple sclerosis treated with autologous CD4+ cells, stimulated and expanded ex vivo by ...
    Medical condition: Multiple sclerosis is an immune-mediated inflammatory disease that attacks myelinated axons in the central nervous system. MS is characterized initially by episodes of reversible neurologic deficit...
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2018-002476-40 Sponsor Protocol Number: 17-APN-01 Start Date*: 2019-05-07
    Sponsor Name:CHU de Nice
    Full Title: Personalized Medicine for Membranous Nephropathy PMMN
    Medical condition: Idiopathic Membranous Nephropathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004857 10027170 Membranous nephropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-005197-19 Sponsor Protocol Number: SIPPET2 Start Date*: 2018-08-01
    Sponsor Name:FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO
    Full Title: Inhibitor development in previously untreated patients with severe haemophilia A, first treated with plasma-derived factor VIII and then switched to recombinant product: an international, multicent...
    Medical condition: Severe hemophilia A
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10018938 Haemophilia A (Factor VIII) LLT
    Population Age: Newborns, Infants and toddlers, Children, Under 18 Gender: Male
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-002571-16 Sponsor Protocol Number: MBP8298-01 Amendment 04 Start Date*: 2007-06-29
    Sponsor Name:BioMS Technology Corp
    Full Title: A double-blind, placebo controlled multicentre study to evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis.
    Medical condition: Secondary progressive multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10063400 Secondary progressive multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed) FI (Completed) DK (Completed) ES (Completed) EE (Completed) NL (Completed) LT (Prematurely Ended) LV (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-017340-14 Sponsor Protocol Number: RHMCAN0700 Start Date*: 2011-07-26
    Sponsor Name:University Hospital Southampton NHS Foundation Trust
    Full Title: WT1 Immunity via DNA fusion Gene Vaccination in Haematological Malignancies by intramuscular injection followed by intramuscular electroporation.
    Medical condition: Chronic myeloid Leukemia and acute myeloid leukemia in cytogentic remission
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-000988-68 Sponsor Protocol Number: O2021-1 Start Date*: 2021-03-31
    Sponsor Name: Region Stockholm
    Full Title: Immune response after covid-19 vaccination in patients with renal failure stadium 4 or 5 .
    Medical condition: Renal failure stage 4 and 5.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2016-002720-91 Sponsor Protocol Number: HBnr02 Start Date*: 2017-09-21
    Sponsor Name:CyTuVax BV
    Full Title: Immunogenicity and safety of HBAI20 Hepatitis B vaccine in non-responders.
    Medical condition: In a minority of the population (5-10%) standard vaccines against Hepatitis-B do not induce protective immunity, even after prolonged and repeated vaccination courses. Non- responsiveness to hepati...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-003191-14 Sponsor Protocol Number: 21CH135 Start Date*: 2021-08-16
    Sponsor Name:CHU SAINT-ETIENNE
    Full Title: Cohort assessing the immunogenicity and the safety of the COVID-19 Vaccine Janssen in healthy volunteers based on 3 age groups: 65 years or older - 55 to 65 years - 18 to 45 years - Covicompare-Jan...
    Medical condition: volunteers
    Disease: Version SOC Term Classification Code Term Level
    23.1 10042613 - Surgical and medical procedures 10084465 COVID-19 vaccination LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-011186-88 Sponsor Protocol Number: ABB-09-001 Start Date*: 2009-09-08
    Sponsor Name:FONDAZIONE CENTRO EMOFILIA E TROMBOSI ANGELO BIANCHI BONOMI
    Full Title: Desarrollo de inhibidores en pacientes no tratados previamente (PUP) o en pacientes mínimamente tratados con componentes sanguíneos (MBCTP) al ser expuestos a concentrados de derivados plasmáticos ...
    Medical condition: El estudio es un ensayo clínico abierto, aleatorizado, controlado, prospectivo, multicéntrico, internacional e independiente sobre la frecuencia de formación de inhibidores en pacientes no tratados...
    Disease: Version SOC Term Classification Code Term Level
    9 10018937 Haemophilia A LLT
    Population Age: Newborns, Infants and toddlers, Children, Under 18 Gender: Male
    Trial protocol: ES (Prematurely Ended) IT (Completed) PT (Completed) FR (Ongoing) DE (Completed) AT (Prematurely Ended) BE (Completed) GB (GB - no longer in EU/EEA) SK (Completed) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-001301-42 Sponsor Protocol Number: 111473 Start Date*: 2009-01-15
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: An open Phase II study to assess the clinical activity and safety of recMAGE-A3 + AS15 cancer immunotherapeutic in patients with metastatic cutaneous melanoma, and to explore its immunogenic proper...
    Medical condition: Adult patients with histologically proven, measurable metastatic cutaneous melanoma (stage III in transit or unresectable, or stage IV M1a), with documented progressive disease within the 12 weeks ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2021-000962-14 Sponsor Protocol Number: CCM-RNT-202101 Start Date*: 2021-07-02
    Sponsor Name:Charité - Universitätsmedizin Berlin
    Full Title: A Monocenter, Open Label Study to Evaluate the Safety and Efficacy of Daratumumab in Combination with Standard Background Therapy in Participants with Moderate to Severe Systemic Lupus Erythematosus
    Medical condition: Systemic Lupus Erythematosus
    Disease: Version SOC Term Classification Code Term Level
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 18 20:29:34 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA